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a  b  s  t  r  a  c  t
Bipolar  disorder  (BD)  is  a debilitating  psychiatric  disease  characterized  by  alternating  episodes  of  mania
and depression.  Among  mood  stabilizers,  lithium  is  the  mainstay  for the  treatment  of BD,  with  approx-
imately  one-third  of patients  showing  remission  from  episode  recurrence.  While  there  is  evidence
suggesting  genetic  load for lithium  response  in  BD,  its molecular  underpinnings  are  still not  completely
understood.  To  identify  genes  potentially  involved  in  (or  correlated  with)  lithium  response,  we carried
out a genome-wide  expression  analysis  on  lymphoblastoid  cell  lines  (LCLs)  from  10 BD  patients  respon-
ders (R)  and 10 non-responders  (NR)  to lithium.  We  compared  expression  levels  of  the  two  groups  and
tested  whether  in  vitro lithium  treatment  had  different  effects  in  LCLs  of R compared  to NR.  At basal,  2060
genes  were  differentially  expressed  between  R and  NR while  no genes  were  differentially  regulated  by
lithium  in  the two  groups.  After  pathway  analysis  based  on the  2060  genes,  9  genes  were  selected  for
validation  with  qRT-PCR.  Eight  genes  were  validated  in  the  same  sample  of LCLs while  only  insulin-like
growth  factor  1  (IGF-1)  was  signiﬁcantly  over-expressed  in R  compared  to  NR  in the  same  sample  as
well  as in  an  independent  sample  comprised  of 6  R and  6  NR  (sample  1, fold  change  = 1.94;  p  = 0.005;
sample  2, fold  change  =  2.21;  p  =  0.005).  IGF-1  was  also  signiﬁcantly  over-expressed  in  R but  not  in NR
when  compared  to a sample  of
in  lithium  response,  supportin
© 201
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. Introduction
Bipolar disorder (BD) is a severe and debilitating psychiatric
isease characterized by extreme changes in mood and behav-
or. It has a prevalence of 0.8–1.2% in the general population
1–3] and constitutes a major cause of disability and premature
ortality [4].
Among mood stabilizers, lithium is considered the ﬁrst line
reatment for acute episodes and maintenance of BD. After more
han 50 years of use there is general consensus that at least 30% of
atients treated in naturalistic settings shows long-term stabiliza-
ion of symptoms [5–7]. However, 50–60% of treated patients have
nsufﬁcient clinical response and require adjunctive or alternative
ood stabilizing therapies [8]. In addition, lithium has a range of
ommon and rare side effects that can have a substantial impact on
ong-term treated patients [9].
In this context, research has focused on the identiﬁcation of pre-
ictors of lithium response in BD. Clinical studies have shown that
ithium responders have distinct clinical features compared to non-
esponders, such as an episodic clinical course, family history of BD
nd absence of rapid cycling [10]. Moreover, response to lithium
ppears to be familial, [11] suggesting that genetic predisposition
ay  constitute a key factor.
The majority of pharmacogenetic studies of lithium response
ave investigated genes putatively involved in the mechanism
f action of lithium or in the etiology of BD while only two
enome-wide association analysis have been performed so far
12]. These studies provided promising ﬁndings for a number of
enes, but replication in independent samples and functional inves-
igations are needed to further explore and clarify their role in
ithium response. Other studies have focused on gene and pro-
ein expression measurements in peripheral tissues such as fresh
lood or lymphoblastoid cell lines (LCLs) sampled from BD patients
haracterized for lithium response. Evidence from these studies
uggested that altered protein levels of brain derived neurotrophic
actor (BDNF) [13] and expression of Synapsin II (SYN2) gene
14,15] may  be involved in lithium response or serve as peripheral
arkers.
Genome-wide investigation of gene expression in complex
henotypes represents a valuable tool in pharmacogenetics as it
as the potential to provide functional-based hypothesis for further
nvestigation. This approach is of particular importance in pharma-
ogenetic studies on drugs that, as lithium, are still the object of
nvestigation to shed light on their mechanism of action. To date,
nly one study carried out a genome-wide expression analysis in
eripheral tissues from BD patients characterized as responders (R)
nd non-responders (NR) to lithium [16]. However, the deﬁnition of
esponse in these patients was based on variations in scores of the
amilton Depression Rating scale during an eight-week open-label
rial. Therefore, ﬁndings from this study are hardly comparable
ith the literature of lithium pharmacogenetics, as these stud-
es used for the most part patients characterized prospectively
r retrospectively for response to maintenance treatment with
ithium.
Here we report the ﬁndings of the ﬁrst genome-wide expres-
ion study in BD patients who were characterized as R and NR to
aintenance treatment with lithium. We  measured expression lev-
ls in LCLs from these patients and compared the two groups. We
lso tested whether in vitro treatment with lithium differentially
ffected the expression patterns in R compared to NR. The top genes
elected from the microarray analysis were tested for validation
y quantitative Real-Time PCR (qRT-PCR) in the same sample of
CLs as well as in an independent sample of BD patients charac-
erized for lithium response. The aim of our study was to identify
enes involved in lithium response and that could constitute new
otential biomarkers.gical Research 73 (2013) 1– 7
2. Materials and methods
2.1. Subjects
Twenty patients with a diagnosis of BD type I (BDI) were selected
from an existing BD sample recruited at the Lithium Clinic of the
Clinical Psychopharmacology Centre of the University Hospital of
Cagliari, Italy. Details of the clinical characterization and assess-
ment of lithium response have been previously published [17].
Brieﬂy, a lifetime consensus diagnosis according to Research Diag-
nostic Criteria (RDC) [18] and DSM-IV [19] criteria was obtained
using personal semi-structured interviews [Schedule for Affective
Disorder and Schizophrenia Lifetime Version (SADS-L)] [20] and a
systematic review of patients’ medical records. Clinical response to
lithium maintenance treatment was assessed using the “Retrospec-
tive Criteria of Long-Term Treatment Response in Research Subjects
with Bipolar Disorder”, as described previously [11,21,22]. Brieﬂy,
the scale measures the degree of improvement in the course of
treatment (score A) weighted against a number of clinical factors
considered relevant in determining whether or not the improve-
ment observed is due to lithium treatment (score B). The degree of
response for each patient is quantiﬁed with a score from 0 to 10
(total score), obtained by subtracting the score B from the score A.
Patients with total score (TS) equal to 7 or higher are considered
responders (R) to treatment.
Of the 20 patients included in this study, 10 were R and 10 were
NR, the latter deﬁned as subjects with a TS equal to 0. A second
sample set of 12 BDI patients (6R and 6 NR, Table 1) was selected
to test for replication the identiﬁed genes. The expression of genes
replicated in the independent sample was  also measured in LCLs
from non-psychiatric controls, comprised of 8 subjects recruited
from blood donors screened with direct interview for the absence
of personal or family history of any psychiatric disorder. The inde-
pendent sample and the control groups were matched for age and
sex with the microarray sample and did not differ for any of the
variables tested (Table 1). The study was  approved by the ethics
committee of the Teaching Hospital of Cagliari (Italy) and informed
written consent was  obtained from all participants.
2.2. Cell cultures
Lymphoblastoid cell lines were established from fresh blood by
transforming lymphocytes with Epstein–Barr virus (EBV) follow-
ing standard procedures [23]. At the reaching of the conﬂuence
state, each cell line was adequately prepared for storage in liquid
nitrogen.
For the present study, LCLs were thawed and regrown in RPMI-
1640 medium, supplemented with 15% fetal bovine serum, 1%
penicillin/streptomycin, 1% l-glutamine 200 mM  and 1% sodium
pyruvate 100 mM (Sigma–Aldrich, St. Louis, MO,  USA). Once LCLs
reached the required cell count (6–9 × 106 cells), two  equivalent
aliquots were transferred into separate ﬂasks, one containing
medium with 1 mM lithium chloride (LiCl) and the other one con-
taining a drug-free medium. Each ﬂask was  cultured at 37 ◦C in a
humidiﬁed incubator with 6% CO2. After 1 week of treatment, in
which continuous presence of 1 mM LiCl was  warranted, cells were
harvested for RNA isolation.
2.3. RNA extraction and microarray procedures
Total RNA was  extracted from cell pellets using TRIreagent solu-
tion (Ambion, Austin, TX) and quantiﬁed with a NanoDrop ND-1000
spectrophotometer (Thermo Fisher, Waltham, MA,  USA). Quality
was considered adequate when the A260/280 ratio was  in the range
of 1.8–2.0. RNA integrity was checked by the Agilent 2100 Bioan-
alyzer (Agilent, Santa Clara, CA, USA) using a RNA 6000 Nano Chip
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Table 1
Demographic and experimental-relevant information of the samples studied.
Microarray sample Independent sample
R NR p R NR p
Subjects (M/F) 10 (5/5) 10 (4/6) ns* 6 (3/3) 6 (2/4) ns*
Age at sampling, yr ± SD 46.6 ± 17.5 40.7 ± 10.0 ns◦ 49.2 ± 6.6 36.5 ± 9.4 nso
LCL frozen storage, yr ± SD 8.8 ± 4.7 13.1 ± 5.2 ns◦ 9.3 ± 5.1 10.3 ± 5.6 nso
R
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C = responders, NR = non responders, yr = years.
* p = p-value of Chi-square.
o Mann–Whitney tests.
nd expressed as RNA Integrity Number (RIN), considered accept-
ble within the range of 7–10.
We used 100 ng of total RNA from each sample to generate a
uriﬁed sense-strand cDNA with incorporated dUTP, by using the
mbion® WT  Expression Kit (Applied Biosystems, Foster City, CA,
SA) following manufacturer’s protocols.
Samples were fragmented and labeled using the Affymetrix
eneChip WT  Terminal Labeling Kit and hybridized to GeneChip®
uman Gene 1.0 ST Arrays (Affymetrix, CA, USA), according to the
anufacturer’s instructions. This chip interrogates 28,869 well-
nnotated genes with 764,885 distinct probes distributed across
he full length of each gene. After 17 h at 45 ◦C in the hybridization
ven, arrays were washed and stained in GeneChip Fluidics Station
50 (Affymetrix, CA, USA) and scanned using GeneChip Scanner
000 7G AutoLoader (Affymetrix, CA, USA). The .CEL ﬁles were gen-
rated and checked using the Affymetrix GeneChip® Command
onsole Software (AGCC) starting from the .DAT ﬁles.
Fig. 1. Analysis ﬂow. LCLs = lymphoblastoid cell lines, R = responders, NR = noSamples were hybridized randomly by a technician blind to the
clinical outcome and in vitro lithium treatment.
2.4. qRT-PCR for validation
One g of total RNA was incubated with DNAse I (Invitrogen,
Carlsbad, CA, USA) to remove any genomic DNA contamination and
cDNA synthesized with the high capacity cDNA reverse transcrip-
tion kit (Applied Biosystems; Foster City, CA, USA). Real Time-PCRs
were run in triplicate using TaqMan Custom Arrays Micro Flui-
dic cards (Applied Biosystems; Foster City, CA, USA) in an ABI
PRISM 7900 HT Sequence Detection System (Applied Biosystems;
Foster City, CA, USA). Speciﬁc information for each probe-set
used for PCRs can be found in Table 1 of the supplementary
material.
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.phrs.2013.04.004.
n responders, Li = lithium, FDR = false discovery rate, FC = fold change.
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Table 2
Pathway analysis with KEGG: comparison of responders versus non-responders.
Comparison of basal expression levels OR  p
Protein processing in endoplasmic reticulum 1.927 0.001
B  cell receptor signaling pathway 2.408 0.001
Inositol phosphate metabolism 2.629 0.002
Prostate cancer 2.152 0.002
Pancreatic cancer 2.291 0.003
Acute myeloid leukemia 2.430 0.003
Colorectal cancer 2.340 0.003
Thyroid cancer 2.997 0.007
Chronic myeloid leukemia 2.011 0.010
Antigen processing and presentation 1.977 0.013
Phosphatidylinositol signaling system 1.903 0.018
Osteoclast differentiation 1.626 0.022
Lysosome 1.634 0.023
Endocytosis 1.461 0.026
Citrate cycle (TCA cycle) 2.437 0.028
SNARE interactions in vesicular transport 2.275 0.029
Other glycan degradation 3.096 0.032
Pathways in cancer 1.335 0.032
Viral myocarditis 1.824 0.032
Folate biosynthesis 4.536 0.034
In this study we conducted a genome-wide expression proﬁling
of lymphoblasts from BD patients responders and non-responders
to maintenance treatment with lithium. Among the genes validated
with qRT-PCR, only IGF-1 was  signiﬁcantly over-expressed in R
Table 3
Genes selected for validation and their pathways according to KEGG analysis.
Gene Pathway
PIK3CG Inositol phosphate metabolism, B cell receptor
signaling pathway
IL2RA Endocytosis
IGF-1 Prostate cancer
HLA-DQB1 Antigen processing and presentation
PARD6G Endocytosis
PLD1 Endocytosis; pathways in cancer
CCNA1 Cell cycle; pathways in cancerA. Squassina et al. / Pharm
.5. Statistics
.5.1. Microarray data analysis
An analysis ﬂow is reported in Fig. 1.
GeneChip data quality control was performed using Expres-
ion Console Software (Affymetrix, CA, USA). Raw data were
reprocessed based on the Robust Multi-array Average algorithm
RMA) for normalization and summarization [24]. Data were ﬁl-
ered to remove duplicated or missing Entrez Ids. Genes were
ested for differential expression between R and NR both at
asal and after in vitro lithium treatment using linear models.
igniﬁcance was deﬁned based on a false discovery rate (FDR)
hreshold of 5% [25]. The analyses were performed using the
ioconductor [26] and the limma  [28] packages implemented in
 software [27].
We carried out pathway analysis using genes showing statis-
ically signiﬁcant difference in the comparison of R versus NR. The
DR threshold of 5% allowed us to include the largest possible num-
er of genes at this step. This approach was employed to implement
 functional-based interpretation of ﬁndings for selecting genes
o be validated. Pathways were identiﬁed based on the hyperge-
metric test for over-representation of speciﬁc terms in the Kyoto
ncyclopedia of Genes and Genomes (KEGG) within the selected
ist of genes.
Genes to be validated with qRT-PCR were selected from the list
enerated by KEGG analyses according to the following criteria:
a) genes comprised in pathways signiﬁcantly over-represented in
he comparison of R versus NR and (b) with fold change (FC) of the
ifference between R and NR ≥1.20 or ≤0.80.
.5.2. qRT-PCR data analysis
Relative expression levels were measured by means of the com-
arative Ct method (Ct) using GAPDH as endogenous control.
old changes of the difference between R and the other groups
ere calculated with 2−Ct equation. Differences between R
nd NR were analyzed with the Mann–Whitney U-test. ANOVA
ith Tukey’s multi comparison test was used to compare the
xpression of R, NR and controls. The signiﬁcance threshold was
et at p < 0.05. Statistical tests were carried out using SPSS sta-
istical software package v20 (SPSS, Inc., Chicago, IL, USA) and
raphPad Prism version 5.00 for Windows, GraphPad Software,
an Diego, CA USA.
. Results
.1. Microarray data and pathway analysis
A total of 2060 genes were differentially expressed between R
nd NR at FDR <5%: 1095 genes were up-regulated and 965 were
own-regulated in R. At the same FDR threshold, no genes were
ifferently inﬂuenced by in vitro lithium treatment in R and NR.
EGG analysis based on the 2060 genes showed that 20 path-
ays were signiﬁcantly over-represented in R compared to NR
Table 2). These pathways comprised 230 genes, of which 120
ad a FC ≥1.20 or ≤0.80: 68 were up-regulated and 44 down-
egulated in R. A complete list of the 230 differentially expressed
enes is reported in Table 2 of the supplementary material.
hosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit
amma  (PIK3CG; FC = 2.52; FDR = 0.0005) was the most sig-
iﬁcantly over-expressed gene in R compared to NR, while
hospholipase D1, phosphatidylcholine-speciﬁc (PLD1) was the
ost under-expressed (FC = 0.31; FDR = 0.016).
Supplementary material related to this article found, in the
nline version, at http://dx.doi.org/10.1016/j.phrs.2013.04.004.The signiﬁcance threshold was  p < 0.05. R = responders, NR = non-responders,
OR  = odds ratio.
3.2. Validation with qRT-PCR
Nine genes were selected for validation among the 120 genes
based on the largest FC in up- or down-regulation. The list of
these genes together with their KEGG pathways is reported in
Table 3. These genes included: PIK3CG, interleukin 2 receptor, alpha
(IL2RA), insulin like growth factor 1 (IGF-1), major histocompati-
bility complex, class II, DQ beta 1 (HLA-DQB1), par-6 partitioning
defective 6 homolog gamma  (PARD6G), PLD1, ms-related tyro-
sine kinase 1 (FLT1), cyclin A1, (CCNA1) and heat shock 70 kDa
protein 1A/1B (HSPA1A/1B). Eight genes were validated by qRT-
PCR in the same sample of LCLs used for the microarray study
(Table 4). Insulin like growth factor 1 (IGF-1) was  validated in
both the microarray and the independent sample, being signiﬁ-
cantly over-expressed in R compared to NR in both samples (sample
1: FC = 1.94; p = 0.005; sample 2: FC = 2.21; p = 0.005). We  there-
fore compared IGF-1 expression levels of R and NR with healthy
controls. IGF-1 was  signiﬁcantly over-expressed in R (FC = 1.63;
p = 0.004; adjusted p = 0.029) but not in NR (FC = 0.68; p = 0.105;
adjusted p = 0.410; Fig. 2).
4. DiscussionsFLT1 Endocytosis
HSPA1A/1B Protein processing in endoplasmic reticulum
Genes selected for validation were the most differentially expressed members of
the reported pathways between the responders and non-responders.
A. Squassina et al. / Pharmacological Research 73 (2013) 1– 7 5
Table 4
Analysis of microarray and qRT-PCR data for basal expression levels in responders and non-responders.
Gene Microarray sample Independent sample
GeneChip qRT-PCR qRT-PCR
FC p FDR* FC p FC p
PIK3CG 2.52 1.0 × 10−5 0.0005 3.03 0.0068 1.55 0.1797
IL2RA 2.46 0.0007 0.0078 2.50 0.0068 2.05 0.2403
IGF-1  2.41 1.6 × 10−6 0.0002 1.94 0.0052 2.21 0.0050
HLA-DQB1 2.06 0.0027 0.0191 1.53 0.3151 0.86 0.9372
PARD6G 2.01 2.6 × 10−6 0.0002 2.99 0.0031 1.12 0.9372
PLD1  0.31 0.0021 0.0163 0.15 0.0011 0.60 0.3939
CCNA1 0.37 0.0001 0.0027 0.18 0.0029 0.67 0.2400
FLT1  0.42 0.0002 0.0041 0.38 0.0001 1.58 0.2823
HSPA1A/1B 0.56 2.5 × 10−9 2.3 × 10−6 0.77 0.0001 0.68 0.3025
p-Values in bold are signiﬁcant at p < 0.05; ns = not signiﬁcant, FC = fold change, FDR = fals
Fig. 2. Relative expression levels of IGF-1. The difference between responders and
non-responders is highly signiﬁcant (***Tukey’s p < 0.0001), while controls differ sig-
n
p
c
i
a
t
a
i
s
l
[
p
c
s
r
o
t
k
(
e
c
d
o
4 (IGFP4), a member of the IGFBP family involved in the regulationiﬁcantly from responders (*Tukey’s p < 0.05) but not from non-responders (Tukey’s
 > 0.05). ns, not signiﬁcant.
ompared to NR in the same sample of patients as well as in an
ndependent sample of patients characterized for lithium response.
IGF-1 belongs to the super-family of insulin like peptides, which
lso comprises IGF-2 and insulin. It is involved in the modula-
ion of a large number of cellular processes including apoptosis,
utophagy, cell metabolism and vesicle trafﬁcking, ultimately lead-
ng to the regulation of development, cell differentiation and
urvival [29].
IGF-1 is locally expressed in all tissues of the body but the circu-
ating form of the protein is mainly produced by liver and pancreas
30]. This peptide crosses the blood-brain barrier but is also highly
roduced in the brain with the highest expression perinatally in
ortex, hippocampus, cerebellum, brainstem, hypothalamus and
pinal cord [31]. In the adult brain the synthesis is reduced but the
egional distribution remains the same as perinatally. The effects
f IGF-1 are primarily mediated by IGF receptor 1 (IGFR1), which
riggers the phosphoinositide 3-Kinase/threonine-serine protein
inase B (PI3K/AKT) and the RAS-mitogen-activated protein kinase
MAPK) signaling pathways [32].
In the pathway analysis based on genes showing differential
xpression between R and NR, IGF-1 was a member of the prostate
ancer pathway. Other 22 genes ascribed to this pathway were
ifferentially expressed between R and NR in our dataset, though
nly IGF-1 was included in the validation analysis, being the moste discovery rate.
signiﬁcantly altered gene between the two  groups. These genes
included elements previously shown to be involved in lithium
mechanism of action, such as mitogen-activated protein kinase
3 (MAPK3), cAMP responsive element binding protein 1 (CREB1),
CREB3, AKT1 and B-cell CLL/lymphoma 2 (BCL2) [33]. Further
investigation is needed to explore whether these genes and their
products play a role in modulating lithium response in BD.
The possible involvement of IGF-1 in BD is suggested by a num-
ber of evidence. IGF-1 gene is located on chromosome 12q23.2,
a region previously reported to be in linkage with BD [34–38].
A recent study also reported positive association between IGF-1
polymorphisms and BD [39]. As lithium, IGF-1 is a potent neuropro-
tective factor, as shown by its beneﬁcial effect in neurodegenerative
processes [40,41], an effect that appears to be mediated by the
activation of the PIK3/AKT pathway [42]. Numerous studies have
also suggested that IGF-1 is involved in ameliorating depression
and anxiety [43–45], likely through the stimulation of neuro-
genesis in the hippocampus [45,46]. Interestingly, neuroimaging
studies have shown that hippocampal volumes are reduced in
BD patients with limited lifetime exposure to lithium, whereas
patients with at least 2 years of exposure had no signiﬁcant dif-
ference with controls [47,48]. Lithium neuroprotection is likely
mediated by the prevention of apoptotic-dependent cellular death
through the interaction with neurotrophic factors and a large num-
ber of signaling pathways, including the PIK3/AKT pathway [49].
The neuroprotective effect of lithium and IGF-1 may  also be medi-
ated by their activity on glycogen synthase kinase 3- (GSK-3).
GSK-3 is a serine-threonine kinase involved in a myriad of cellular
processes including apoptosis, cell differentiation and neurogen-
esis [50]. GSK-3 is one of the most studied targets of lithium
and substantial evidence supports that inhibition of GSK-3 is
an important mechanism in treatments for mood disorders [51].
Recent evidence showed that both lithium and IGF-1 inhibit GSK-
3 in vitro in breast cancer cells through two  different mechanisms:
IGF-1 activates the PI3K/AKT and extracellular signal-regulated
kinases (ERK) pathways while lithium directly inhibits GSK-3
through a magnesium-competitive mechanism [52].
In our study, IGF-1 was over-expressed in R compared to NR
while lithium treatment in vitro did not inﬂuence IGF-1 expres-
sion. IGF-1 was  also signiﬁcantly over-expressed in R compared to
healthy controls. These ﬁndings suggest that an over-expression
of IGF-1 may  be necessary for lithium to exert its effect and NR
may  have no sufﬁcient IGF-1 activity to respond properly to lithium
treatment. Lithium and IGF-1 may  have a synergic effect on GSK-3
inhibition. Interestingly, in our microarray data IGF binding proteinof IGF bioavailability, was  under-expressed in R compared to NR
(FC = 0.72, FDR = 0.007). IGFBP4 binds to IGF-1 with high afﬁnity
partially masking IGF residues responsible for the binding to IGFR1
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53]. Although IGFBP4 was not selected for validation with qRT-PCR
n our study, we  could speculate that lithium responders may  be
haracterized by a higher sensitivity to lithium as a consequence
f an over-reactive IGF-1 pathway. An important future step of our
tudy would be to explore different members of IGF-1 pathway and
nvestigate whether their activity differs in patients with R and NR
o lithium.
In the present study we also treated LCLs with lithium for 1 week
ith the purpose of perturbing the resting state of LCLs to highlight
ithium-induced differences between R and NR in gene expression
atterns. No signiﬁcant gene was identiﬁed at a 5% FDR threshold,
uggesting that in our sample the effect of lithium does not dif-
er appreciably between LCLs from patients with different clinical
esponse to long-term treatment. While we were able to observe
ifferences between R and NR, this difference was not statistically
igniﬁcant.
Our ﬁndings must be interpreted in light of some limitations.
irstly, the sample size of the study was likely underpowered for
etecting small effect sizes. Secondly, while the use of LCLs for phar-
acogenetic studies presents valuable strengths, it also has some
imitations. On one hand, LCLs allow controlling for non-genetic
actors that could greatly interfere with gene expression in fresh
lood cells, such as diet and pharmacological treatments in patients
54]. Cultured cell lines can also be used for in vitro assays of drug
ffects. On the other hand, EBV transformation is known to lead to
he production of viral proteins that may  inﬂuence gene expression
55,56]. Moreover, low correlation between gene expression pat-
erns in LCLs and brain has been reported [57]. While this aspect
oes not limit their use for the search of peripheral correlates and
iomarkers of disorders of the central nervous system, it impacts
heir suitability as a model for exploring neuronal mechanisms.
. Conclusions
In conclusion, our study suggests that the over-expression of
GF-1 might be a biological marker of response to long-term treat-
ent with lithium. Further investigation in larger independent
amples is warranted to conﬁrm our ﬁndings.
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